On the Translation of a Treatment's Effect on Disease Progression Into an Effect on Overall Survival

Authors

  • Steven M. Snapinn Global Biostatistical Science, Amgen, Thousand Oaks, CA 91320, USA
  • Qi Jiang Global Biostatistical Science, Amgen, Thousand Oaks, CA 91320, USA

DOI:

https://doi.org/10.6000/1929-6029.2015.04.01.8

Keywords:

Oncology, Overall survival, Progression-free survival, Restricted mean, Bevacizumab.

Abstract

There are many examples of treatments for cancer that show a large and statistically significant improvement in progression-free survival (PFS) but fail to show a benefit in overall survival (OS). One recent example that has received considerable attention involves bevacizumab (Avastin) for the treatment of breast cancer. While it seems logical that slowing the rate of progression of a fatal disease would translate into an increase in survival, it is not clear what relative magnitudes of these two effects one should expect. One potential model for the translation of a benefit on disease progression into an OS benefit assumes that patients transition from a low-risk state (pre-progression) into a high-risk state (post-progression), and that the only impact of the treatment is to alter the rate of this transition. In this paper we describe this model and present quantitative results, using an assumption of constant hazards both pre-progression and post-progression. We find that an effect on progression translates into an effect on survival of a smaller magnitude, and that two key factors influence that relationship: the magnitude of the difference between the hazard rate for death in the pre- and post-progression states, and the duration of follow-up.

References

Soria JC, Massard C, Le Chevalier T. Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Annals of Oncology 2010; 21: 2324-2332. http://dx.doi.org/10.1093/annonc/mdq204 DOI: https://doi.org/10.1093/annonc/mdq204

Halabi S, Vogelzang NJ, Ou S-S, Owzar K, Archer L, Small EJ. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. Journal of Clinical Oncology 2009; 27: 2766-2771. http://dx.doi.org/10.1200/JCO.2008.18.9159 DOI: https://doi.org/10.1200/JCO.2008.18.9159

Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück, H-J, Mackey JR, Nabholtz J-M, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran A, Therasse P. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate endpoints in metastatic breast cancer. Journal of Clinical Oncology 2008; 26: 1987-1992. http://dx.doi.org/10.1200/JCO.2007.10.8407 DOI: https://doi.org/10.1200/JCO.2007.10.8407

Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon J-P, Piedbois P. Progression-free survival is a surrogate for survival in advanced colorectal cancer. Journal of Clinical Oncology 2007; 25: 5218-5224. http://dx.doi.org/10.1200/JCO.2007.11.8836 DOI: https://doi.org/10.1200/JCO.2007.11.8836

Halabi S, Rini B, Escudier B, Stadler WM, Small EJ. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer 2014; 120: 52-60. http://dx.doi.org/10.1002/cncr.28221 DOI: https://doi.org/10.1002/cncr.28221

Dienstmann R, Ades F, Saini KS, Metzger-Filho O. Benefit risk assessment of bevacizumab in the treatment of breast cancer. Drug Safety 2012; 35: 15-25. http://dx.doi.org/10.2165/11595910-000000000-00000 DOI: https://doi.org/10.2165/11595910-000000000-00000

Chen C, Sun LZ. Quantification of PFS effect for accelerated approval of oncology drugs. Statistics in Biopharmaceutical Research 2011; 3: 434-444. http://dx.doi.org/10.1198/sbr.2011.09046 DOI: https://doi.org/10.1198/sbr.2011.09046

Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. Journal of Clinical Oncology 2009; 27: 2874-2880. http://dx.doi.org/10.1200/JCO.2008.20.4107 DOI: https://doi.org/10.1200/JCO.2008.20.4107

Tang Y, Bycott P, Akerborg O, Jonsson L, Negrier S, Chen C. Interpreting overall survival results when progression-free survival benefits exist in today’s oncology landscape: a metastatic renal cell carcinoma case study. Cancer Management Research 2014; 6: 356-371.

Fleischer F, Gaschler-Markefski B, Bluhmki E. A statistical model for the dependence between progression-free survival and overall survival. Statistics in Medicine 2009; 28: 2669-2686. http://dx.doi.org/10.1002/sim.3637 DOI: https://doi.org/10.1002/sim.3637

Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. Journal of the National Cancer Institute 2009; 101: 1642-1649. http://dx.doi.org/10.1093/jnci/djp369 DOI: https://doi.org/10.1093/jnci/djp369

Redman MW, Goldman BH, LeBlanc, M, Schott, A, Baker LH. Modeling the relationship between progression-free survival and overall survival: the phase II/III trial. Cancer Clinical Research 2013; 19: 2646-2656. http://dx.doi.org/10.1158/1078-0432.CCR-12-2939 DOI: https://doi.org/10.1158/1078-0432.CCR-12-2939

Zhang L, Ko C-W, Tang S, Sridhara R. Relationship between progression-free survival and overall survival benefit: a simulation study. Therapeutic Innovation and Regulatory Science 2013; 47: 95-100. http://dx.doi.org/10.1177/0092861512459180 DOI: https://doi.org/10.1177/0092861512459180

Dejardin D, Lesaffre E, Verbeke G. Joint modeling of progression-free survival and death in advanced cancer clinical trials. Statistics in Medicine 2010; 29: 1724-1734. http://dx.doi.org/10.1002/sim.3918 DOI: https://doi.org/10.1002/sim.3918

Downloads

Published

2015-01-27

How to Cite

Snapinn, S. M., & Jiang, Q. . (2015). On the Translation of a Treatment’s Effect on Disease Progression Into an Effect on Overall Survival. International Journal of Statistics in Medical Research, 4(1), 72–78. https://doi.org/10.6000/1929-6029.2015.04.01.8

Issue

Section

General Articles